CERENOME, INC. — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Plus Therapeutics rebranded to Cerenome, Inc. (Nasdaq: CNSY) effective August 3, 2026. Q2 2026 net loss was $9.0M ($1.31/share) vs. Q2 2025 net income of $5.2M ($0.62/share); operating loss expanded to $9.1M from $1.5M YoY, driven by CNSide diagnostics commercial buildout and REYOBIQ Phase 2 trial costs. Cash position declined from $8.8M (Dec 31, 2025) to $2.4M (June 30, 2026); company raised $16.9M via underwritten offering and distribution agreement in H1 2026.
Why this rating
Large operating loss expansion (~6x YoY) and cash burn rate material to $31.9M market cap; near-term liquidity stress evident. Rebranding and diagnostic/therapeutic platform progress provide strategic optionality but near-term dilution and burn rate pose going-concern risk.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.